CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a company pioneering the discovery and development of small molecules that bind to exosites, today announced the appointment of Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy. Bailey served as an independent strategy advisor to Exo prior to this full-time transition.
“Dorothy Lou is a phenomenal addition to our team. She has been an integral advisor to Exo and we relied on her expertise and perspective in completing our recent Series B financing,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Our entire team is incredibly fortunate to work with her as a full-time team member, especially as we look to enter the clinic and expand our company.”
“It has been a pleasure to work with Exo over the last year and I am thrilled to join the team full-time,” said Bailey. “Exosites are compelling therapeutic targets and provide an innovative way to address common challenges we have seen with active site modulators. I look forward to working with the team on realizing the enormous potential of exosites and creating a new class of exosite-targeting medicines that span therapeutic areas.”
Bailey brings over 10 years of experience in creating enduring value for biotech and pharmaceutical companies. Prior to joining Exo, she worked as a corporate development and strategy consultant for VC firms and biotech companies. Bailey also served in positions of increasing responsibility, ultimately as Head of Corporate Development at Blackthorn Therapeutics where she secured a $76 million financing and managed corporate strategy, licensing, search and evaluation. Before Blackthorn, she served as Principal at The Reckon Group, where she closed over $100 million in funding and co-development contracts as well as led new business development and capital strategy within the biopharmaceutical markets. Bailey earned her Bachelors with honors in Biology, Biochemistry & Molecular Genetics from Duke University.
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit.